2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2234

Osteoporosis Screening in a Resident-Driven Clinic of a Large Academic Hospital
Abstract Number: 2235

Osteoporosis Screening in African American Patients of Rheumatoid Arthritis Patients: Are We Doing Enough?
Abstract Number: 2236

Strength Training for People with Rheumatoid Arthritis: Barriers, Facilitators, and Tailoring Considerations
Abstract Number: 2237

Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies
Abstract Number: 2238

Role of Clinical Impact, Disease-specific Knowledge and Beliefs About Medication on Therapeutic Adherence in Rheumatoid Arthritis: An Integrative Structural Equation Modeling Approach
Abstract Number: 2239

Reproductive Health Awareness and Needs: Assessment of Parents, Female Adolescents, and Young Adults with Pediatric Rheumatic Diseases
Abstract Number: 2240

Mining Social Media Data to Investigate Patient Perceptions Regarding DMARD Pharmacotherapy for Rheumatoid Arthritis
Abstract Number: 2241

Parent Perspectives on Addressing Emotional Health for Youth with Juvenile Myositis: A Qualitative Focus Group Study
Abstract Number: 2242

Evaluating Important Change in Cutaneous Disease Activity as an Efficacy Measure for Clinical Trials in Dermatomyositis
Abstract Number: 2243

Knowledge, Needs and Expectations Among Systemic Lupus Erythematosus: Preliminary Results from the INTEGRATE Pilot Project
Abstract Number: 2244

What Are the Prescribing Trends and Satisfaction Levels with Analgesics for Osteoarthritis as Reported by US Rheumatogists, Orthopaedic Surgeons, and Primary Care Physicians?
Abstract Number: 2245

Polymyositis (PM) and Dermatomyositis (DM) Symptom Flares and Associated Impact from the Patient Perspective
Abstract Number: 2246

Symptoms and Impacts in Psoriatic Arthritis: Findings from Qualitative Patient Interviews
Abstract Number: 2247

Patient Factors Associated with Willingness to Change Rheumatoid Arthritis Medications
Abstract Number: 2248

Legal Matters: Attitudes Regarding Marijuana for Medical Use Among Patients with Rheumatic and Musculoskeletal Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].